Jennifer E. Mason, RN, MS, has been appointed as Vice President of Clinical Operations at Atherotech Inc.

Mason will focus on building the disease management and clinician services departments at the cardiodiagnostic company known for its patented VAP® Cholesterol Test. This new position is also responsible for developing programs to educate the public and health care professionals about Atherotech’s line of cardiometabolic tests.

Mason comes to Atherotech with eight years experience from Berkeley HeartLab Inc, a leading competitor in the advanced lipid profile market. As a clinician, she brings practical experience in cardiology and heart disease management with her to Atherotech.

Mason is a member of the American College of Cardiology and the Preventive Cardiovascular Nurses Association. She is the lead author of a review paper, "Gamma Glutamyl Transferase: A Novel Cardiovascular Risk Biomarker" to be published shortly in the journal, Preventive Cardiology.

Mason will work closely with Atherotech’s Chief Medical Officer Michael Cobble, MD, and report to CEO Mike Mullen.

"Jennifer’s strong clinical, managerial, and investigative skills will positively move Atherotech forward as a leader in cardiovascular disease management," Mullen said.

Atherotech recently added the PLAC Test for identification of increased heart attack and stroke risk and the cystatin C test as an early, sensitive marker for chronic kidney disease. Other cardiometabolic and genetic tests now available through Atherotech include C-Reactive Protein (hsCRP), apoE genotype, NT-proBNP, creatinine, creatine kinase (CK), HbA1c, insulin, TSH, ALT, AST, blood urea nitrogen (BUN), glucose, vitamin D and homocysteine. Cardiometabolic test panels can be ordered individually or bundled as part of a custom risk profile that also includes the advanced VAP Cholesterol Test.

Source: Atherotech